Enlarged Prostate, Inflammation and Other Common Reasons PSA Runs High

Few lab results cause as much worry as an elevated prostate-specific antigen, or PSA, level. The PSA test is a simple blood test, and for many men it’s the first step in prostate cancer screening. That’s why a higher-than-expected number can feel alarming.

But a high result isn’t a cancer diagnosis, according to Brandon Mancini, M.D., MBA, medical director at BAMF Health. Many of the reasons PSA rises have nothing to do with cancer, and doctors are increasingly careful about confirming a result before moving to more invasive testing.

An Enlarged Prostate Is a Frequent Culprit

According to Mancini, the most common benign explanation for an elevated PSA is often benign prostatic hyperplasia, or BPH, which is an enlarged prostate.

“PSA is produced by prostate tissue, not specifically by prostate cancer cells, so a larger prostate can naturally produce more PSA,” he said.

Other things can temporarily push PSA higher too. These include inflammation or infection, urinary retention and recent instrumentation, such as a procedure involving the urinary tract. Because these causes can come and go, a single reading doesn’t always reflect what’s happening in the prostate over time.

Confirming the Result Before Imaging or Biopsy

Because PSA can fluctuate, the American Urological Association (AUA) has moved toward repeating a newly elevated test before ordering imaging or a biopsy.

“Approximately 25% to 40% of newly elevated PSA levels may return to a normal range when repeated,” Mancini said.

He said confirming that an elevation is real and persistent can spare patients unnecessary anxiety, imaging, testing and biopsies. It still identifies the patients who need further evaluation. For patients, that means a high first result is usually a reason for a follow-up test, not an immediate leap to a biopsy.

A Risk Marker, Not a Diagnosis

Mancini wants patients to understand what the test does and doesn’t tell them.

“A PSA is not a cancer test in the sense that a positive result means you have cancer,” he said. “It is a marker of prostate activity and a tool we use to estimate risk.”

An elevated result means doctors should look into why it’s elevated, and there are many benign explanations. Even when more evaluation is needed, the goal is increasingly to find clinically significant prostate cancer. That means avoiding unnecessary procedures and treatment for disease that is unlikely to cause harm.

Screening Is Shifting Toward Individual Risk

Mancini noted that the AUA and Society of Urologic Oncology recommendations on starting ages were already part of the 2023 guideline. They recommend considering a baseline PSA between ages 45 and 50 for average-risk men, and starting screening between ages 40 and 45 for higher-risk men.

The 2026 amendment continues the shift toward earlier, individualized, risk-based screening, rather than the same starting age and testing interval for everyone. He said screening should be a shared decision between patient and clinician. It should take into account a person’s age, family history, ancestry, genetic risk, overall health and preferences.

Higher-Risk Men Shouldn’t Wait for Symptoms

For men at increased risk, Mancini’s advice is direct: “Don’t wait for symptoms.”

Early prostate cancer usually causes no symptoms, which is why screening can matter. Higher-risk groups include Black men, men with a strong family history of prostate cancer and men with certain inherited genetic mutations. Mancini said these men should generally start the screening conversation with their clinician around ages 40 to 45.

“Starting the conversation earlier doesn’t mean that something is wrong; it allows us to establish a baseline and develop a screening strategy tailored to that person’s individual risk,” he said.

Whether a man is at average or higher risk, Mancini’s message is the same: A PSA number is a starting point for a conversation with a clinician, not a verdict.